Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Bank of New York Mellon Corp Reduces Stock Position in Denali Therapeutics Inc (NASDAQ:DNLI)
09:12am, Wednesday, 15'th Apr 2020
Bank of New York Mellon Corp reduced its position in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the Secu
Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
10:08pm, Thursday, 09'th Apr 2020
Sean McCarthy, president and CEO of CytomX Therapeutics Inc.
Denali Therapeutics Inc (NASDAQ:DNLI) Shares Sold by AQR Capital Management LLC
08:32am, Thursday, 09'th Apr 2020
AQR Capital Management LLC trimmed its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 28.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commissi
Don’t Ignore The Fact That This Insider Just Sold Some Shares In Denali Therapeutics Inc. (NASDAQ:DNLI)
12:43pm, Saturday, 04'th Apr 2020
We note that the Denali Therapeutics Inc. (NASDAQ:DNLI) Co-Founder, Ryan Watts, recently sold US$94k worth of stock...
Ryan J. Watts Sells 4,807 Shares of Denali Therapeutics Inc (NASDAQ:DNLI) Stock
09:06am, Saturday, 04'th Apr 2020
Denali Therapeutics Inc (NASDAQ:DNLI) CEO Ryan J. Watts sold 4,807 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $19
Credit Suisse AG Sells 5,894 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)
08:24am, Saturday, 04'th Apr 2020
Credit Suisse AG cut its holdings in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 12.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exc
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by ValuEngine
07:20am, Saturday, 04'th Apr 2020
Denali Therapeutics (NASDAQ:DNLI) was upgraded by ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Thursday, ValuEngine reports. DNLI has been the subject of sever
Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to Hold at Zacks Investment Research
06:42am, Saturday, 04'th Apr 2020
Denali Therapeutics (NASDAQ:DNLI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. According to Zacks, �
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
11:36am, Friday, 03'rd Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biote
Denali Therapeutics (NASDAQ:DNLI) Rating Increased to Buy at Zacks Investment Research
09:00am, Friday, 03'rd Apr 2020
Zacks Investment Research upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a hold rating to a buy rating in a research report released on Monday morning, Zacks.com reports. Zacks Investment R
Denali Therapeutics Inc (NASDAQ:DNLI) Expected to Announce Quarterly Sales of $5.93 Million
08:22am, Friday, 03'rd Apr 2020
Equities research analysts predict that Denali Therapeutics Inc (NASDAQ:DNLI) will report sales of $5.93 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have is
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
12:00am, Friday, 03'rd Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 2)
BELLUS Health Inc (NASDAQ:...
BRIEF-Denali Therapeutics Says Paused Enrollment in Phase 1, Phase 1B Trials Due To Covid-19
08:55pm, Thursday, 02'nd Apr 2020
Denali Therapeutics Inc:
Still more COVID-19 actions - healthcare
08:44pm, Thursday, 02'nd Apr 2020
Molina Healthcare (NYSE:MOH) is providing virtual urgent care to Marketplace members vis its partnership with Teladoc (NYSE:TDOC) and is expanding Teladoc to all Medicare and Medicaid members. It is c
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
08:30pm, Thursday, 02'nd Apr 2020
“In these unprecedented times, our resolve to defeat degeneration is undiminished and our top priority is to ensure the health and safety of our employees, community, partners and clinical trial par
